The Real Story cover image

How close are we to ending Alzheimer's?

The Real Story

00:00

The Cost of Alzheimer's Treatments

The DINANIMAB significantly slowed cognitive and functional decline in early symptomatic Alzheimer's disease. The drugs rely on early diagnosis and the cost per patient is high, will governments want to pay? And what risk do patients run if they choose to try these medicines? "You get some brain swelling immediately after often the first or second dose"

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app